Strategic analysis
Internal audit
Improvement actions after review, to prevent recurrence
Calibration and process progress
Quality committee quality evaluation
INQUIRIES |
MicrobiotiX committed to developing bacteriophage‑based therapies for tackling global intractable diseases, particularly multidrug‑resistant bacterial infections.
MicrobiotiX committed to developing bacteriophage-based therapies for tackling global intractable diseases, particularly multidrug‑resistant bacterial infections.
MicrobiotiX MicrobiotiX is dedicated to developing bacteriophage-based therapeutics targeting multidrug-resistant pathogens. We have established a comprehensive platform for drug discovery and development, including a bacteriophage library, in-silico modules, and a GMP-certified manufacturing facility. With these core capabilities, we are advancing innovative therapies in the field of phage and microbiome science to address critical unmet medical needs. More  |
MicrobiotiX MicrobiotiX is dedicated to developing bacteriophage-based therapeutics targeting multidrug-resistant pathogens. We have established a comprehensive platform for drug discovery and development, including a bacteriophage library, in-silico modules, and a GMP-certified manufacturing facility. With these core capabilities, we are advancing innovative therapies in the field of phage and microbiome science to address critical unmet medical needs. More |
BACTERIOPHAGE
MicrobiotiX
MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.
BACTERIOPHAGE
MicrobiotiX
MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.
GMP FACILITY
Quality Control
GMP FACILITY
Quality Control
| INQUIRIES |